Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Managing cardiotoxicity while treating cancer

Bookmark and Share
Published: 18 Mar 2009
Views: 11527
Rating:
Save
Dr Carlo Cipolla - Director of the Cardioncology Division, European Institute of Oncology, Milan

Dr Carlo Cipolla, head of the International Cardioncology Society, talks to ecancer about the new field, his work at the IEO, and collaborations.

Related Videos

Choosing Wisely in hemato-medical oncology
Dr Omar Abdihamid - Garissa Cancer Centre, Garissa, Kenya
Choosing Wisely in hemato-medical oncology ( Dr Omar Abdihamid - Garissa Cancer Centre, Garissa, Kenya )
28 Mar 2023
Haemopathy burden in the National Cancer Center of Cambodia
Dr Vannarith Kao - Calmette Hospital, Phnom Penh, Cambodia
Haemopathy burden in the National Cancer Center of Cambodia ( Dr Vannarith Kao - Calmette Hospital, Phnom Penh, Cambodia )
20 Mar 2023
Choosing wisely in multiple myeloma
Dr Bishesh Poudyal - Civil Service Hospital, Kathmandu, Nepal
Choosing wisely in multiple myeloma ( Dr Bishesh Poudyal - Civil Service Hospital, Kathmandu, Nepal )
20 Mar 2023
Multiple myeloma
Dr Bishesh Poudyal - Civil Service Hospital, Kathmandu, Nepal
Multiple myeloma ( Dr Bishesh Poudyal - Civil Service Hospital, Kathmandu, Nepal )
16 Mar 2023
Choosing Wisely in multiple myeloma
Dr Hamisa Iddy - Ocean Road Cancer Institute, Dar es Salaam, Tanzania
Choosing Wisely in multiple myeloma ( Dr Hamisa Iddy - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )
8 Mar 2023
ZUMA-7: Axi-cel is superior to standard of care across common prognostic...
Dr Fred Locke - Moffitt Cancer Center, Tampa, USA
ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )
23 Dec 2022
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of...
Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL ( Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA )
21 Dec 2022
PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival...
Dr Monzr Al Malki - City of Hope, Duarte, USA
PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival compared to Tac/MTX in graft-versus-host disease  ( Dr Monzr Al Malki - City of Hope, Duarte, USA )
21 Dec 2022
Effective treatment of low risk acute GVHD with itacitinib monotherapy
Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA
Effective treatment of low risk acute GVHD with itacitinib monotherapy ( Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA )
21 Dec 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation